Microfluidic integrated with optical trappings, electrophoresis, dielectrophoretic and immunocapture technology has been reported for the detection of cancer specific exosomes (CD9, CD63, CD53, CD23, EpCAM and, HER2-positive) from blood plasma of breast cancer patients [133,134]. Here, ERBB2 is linked to breast cancer.